Study to Investigate Long-term Pulmonary and Extrapulmonary Effects of COVID-19
NCT ID: NCT04581135
Last Updated: 2023-03-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
620 participants
OBSERVATIONAL
2020-05-01
2022-01-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Severe Acute Respiratory Syndrome (SARS-CoV-2/COVID-19) Related Pneumonia on Lung Function and Structure.
NCT04916834
Long-term Pulmonary Outcomes After Infection With Sars-CoV-2
NCT04401163
International SARS-CoV-2 (COVID-19) Infection Observational Study
NCT04385251
Evaluation of the Safety and Outcomes of Outpatient Management With Mild to Moderate COVID-19 Pneumonia
NCT04542044
Follow-up of Respiratory Sequelae of Hospitalized Patients With COVID-19
NCT04505631
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
COVID-19 Lung
COVID-19 survivors in Switzerland
COVID-19
Research project in which biological material is sampled and health-related personal data are collected and used for further research. Coded data are used.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
COVID-19
Research project in which biological material is sampled and health-related personal data are collected and used for further research. Coded data are used.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* All adult patients with COVID-19 over 18 years.
Exclusion Criteria
* Pregnancy.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Insel Gruppe AG, University Hospital Bern
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Manuela Funke-Chambour, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital Bern, Department of Pulmonary Medicine - Lead Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St. Claraspital AG - Department of Pulmonary Medicine
Basel, , Switzerland
Universtiy Hospital Bern (Inselspital), Department of Pulmonary Medicine - Lead Center
Bern, , Switzerland
University and Hospital of Fribourg
Fribourg, , Switzerland
Hôpitaux Universitaires de Genève - Service de Pneumologie
Geneva, , Switzerland
CHUV - Service de Pneumologie
Lausanne, , Switzerland
Clinica Moncucco
Lugano, , Switzerland
Kantonspital St. Gallen - Klinik für Pneumologie und Schlafmedizin Lungenzentrum
Sankt Gallen, , Switzerland
Hôpital du Valais - Service de Pneumologie
Sion, , Switzerland
Universitätsspital Zürich - Klinik für Pneumologie
Zurich, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Abu Hussein N, Machahua C, Ruchti SC, Horn MP, Piquilloud L, Prella M, Geiser TK, von Garnier C, Funke-Chambour M. Circulating calprotectin levels four months after severe and non-severe COVID-19. BMC Infect Dis. 2023 Oct 3;23(1):650. doi: 10.1186/s12879-023-08653-7.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-00799
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.